Effect of deslorelin-induced pubertal delay on the growth of adolescents with short stature and normally timed puberty: preliminary results

What Was Tested

Researchers studied Triptorelin and Deslorelin in this randomized controlled trial publication.

To determine whether pubertal delay induced by LHRHa can enhance final height in patients with short stature and a normally timed puberty, the researchers enrolled 43 short children (28 girls and 15 boys) in a double blind, placebo-controlled trial.

Why It Was Studied

This report describes the preliminary results in 16 children who have completed 4 yr of treatment (9 patients in the deslorelin group and 7 patients in the placebo group).

Who Took Part

According to the abstract, 43 children were involved.

By PubMed's age tags, the people studied were teenagers, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Triptorelin and who got the comparison, which limits bias.

Neither the children nor the staff measuring them knew who was on Triptorelin, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Triptorelin group a baseline to be compared against.

What Was Measured

The subject headings attached to it are Body Height, Bone Development, Forecasting, Gonadal Steroid Hormones, Gonadotropin-Releasing Hormone, Gonadotropins and Puberty.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Triptorelin and Deslorelin in 43 children.

The publication is from 1993 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Triptorelin compound page and the Deslorelin compound page, all human trials.